Physician profile
Constance M Mobley
NPI 1932228848
$55,941.23
in general payments reported to CMS, 2019-2025
41 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $11K · 2021: $7,731 · 2022: $1,460 · 2023: $30K · 2024: $2,981 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $3,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,800.00 |
| Food and Beverage | $3,494.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $47,269.58 | 2020-2025 | Terlivaz |
| Saol Therapeutics INC. | $1,328.00 | 2020 | |
| Merck Sharp & Dohme LLC | $1,002.94 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $990.21 | 2021-2025 | |
| Gilead Sciences, INC. | $850.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $471.97 | 2019-2022 | |
| Eisai INC. | $412.46 | 2019-2024 | |
| Allergan, INC. | $381.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.34 | 2019-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $225.94 | 2022-2025 | Ultomiris, Soliris |
| Tela Bio, INC. | $216.76 | 2020-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Shionogi INC | $209.24 | 2019-2020 | |
| Astellas Pharma US INC | $188.94 | 2019-2024 | Cresemba |
| Smith+Nephew, INC. | $187.00 | 2022-2024 | Stravix Pl, Oasis, Stravix |
| Intercept Pharmaceuticals, INC. | $184.13 | 2023-2025 | Ocaliva |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $167.41 | 2021 | |
| Baxter Healthcare | $140.67 | 2023-2025 | Perclot |
| Biom'Up France Sas | $131.38 | 2020 | |
| Vifor Pharma, INC. | $118.01 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $111.14 | 2025 | Giapreza |
| Boston Scientific Corporation | $109.75 | 2021-2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Melinta Therapeutics, LLC | $95.58 | 2023-2024 | Vabomere, Rezzayo |
| Takeda Pharmaceuticals U.S.A., INC. | $95.33 | 2020-2025 | Livtencity |
| Biocompatibles, INC. | $85.08 | 2019 | |
| Intra-Sana Laboratories | $81.89 | 2021-2022 | |
| Kamada LTD. | $75.67 | 2023 | |
| Teleflex LLC | $72.65 | 2022 | |
| Dilon Technologies, INC. | $67.89 | 2025 | Hemoblast Bellows |
| Madrigal Pharmaceuticals | $57.78 | 2024-2025 | Resmetirom, Rezdiffra |
| Medtronic, INC. | $56.31 | 2022 | |
| Integra Lifesciences Corporation | $41.72 | 2023 | Codman Certas, Codman Hakim, Cusa Clarity |
| Kerecis Limited | $40.17 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Octapharma USA, INC. | $31.87 | 2019 | |
| Davol INC. | $29.98 | 2023 | Phasix Mesh |
| Alcresta Therapeutics, INC. | $29.74 | 2024 | Relizorb |
| Pacira Pharmaceuticals Incorporated | $25.83 | 2025 | Exparel |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $16.16 | 2019 | |
| Avanos Medical | $15.81 | 2023 | Cortrak |
| Mirum Pharmaceuticals, INC. | $15.68 | 2025 | Livmarli |
| Acell, INC. | $13.35 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.